Betty Balikagala
Overview
Explore the profile of Betty Balikagala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Awor P, Coppee R, Khim N, Rondepierre L, Roesch C, Khean C, et al.
Antimicrob Agents Chemother
. 2024 Jul;
68(8):e0165923.
PMID: 39028193
Artemisinin-based combination therapies (ACTs) were introduced as the standard of care for uncomplicated malaria in Africa almost two decades ago. Recent studies in East Africa have reported a gradual increase...
2.
Yoshida N, Kikuchi H, Hirai M, Balikagala B, Anywar D, Taka H, et al.
Biochem Pharmacol
. 2024 May;
225:116243.
PMID: 38697310
The spread of malarial parasites resistant to first-line treatments such as artemisinin combination therapies is a global health concern. Differentiation-inducing factor 1 (DIF-1) is a chlorinated alkylphenone (1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl) hexan-1-one) originally...
3.
Fukuda N, Yoshida N, Balikagala B, Tsuru I, Ikeda M, Hirai M, et al.
J Antimicrob Chemother
. 2024 Apr;
79(6):1418-1422.
PMID: 38661223
Objectives: Artemisinin-resistant Plasmodium falciparum malaria is currently spreading globally, including in Africa. Artemisinin resistance also leads to resistance to partner drugs used in artemisinin-based combination therapies. Sequencing of kelch13, which...
4.
Arisue N, Palacpac N, Ntege E, Yeka A, Balikagala B, Kanoi B, et al.
Front Cell Infect Microbiol
. 2023 Jan;
12:1058081.
PMID: 36590593
BK-SE36, based on serine repeat antigen 5 (SERA5), is a blood-stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in Uganda and Burkina Faso have demonstrated...
5.
Fukuda N, Balikagala B, Ueno T, Anywar D, Kimura E, Palacpac N, et al.
Clin Infect Dis
. 2022 Dec;
76(9):1585-1593.
PMID: 36519341
Background: Artemisinin-resistant Plasmodium falciparum is spreading in Southeast Asia and Africa. In vivo susceptibility to artemisinin is studied by looking at the rate of decline of peripheral parasitemia (parasite clearance...
6.
Mita T, Fukuda N, Balikagala B
N Engl J Med
. 2022 Apr;
386(14):1386.
PMID: 35388683
No abstract available.
7.
Coppee R, Bailly J, Sarrasin V, Vianou B, Zinsou B, Mazars E, et al.
Clin Infect Dis
. 2022 Feb;
75(7):1242-1244.
PMID: 35213688
A returned traveler to Uganda presented with a Plasmodium falciparum kelch13 A675V mutant infection that exhibited delayed clearance under artesunate therapy. Parasites were genetically related to recently reported Ugandan artemisinin-resistant...
8.
Balikagala B, Fukuda N, Ikeda M, Katuro O, Tachibana S, Yamauchi M, et al.
N Engl J Med
. 2021 Sep;
385(13):1163-1171.
PMID: 34551228
Background: In the six Southeast Asian countries that make up the Greater Mekong Subregion, has developed resistance to derivatives of artemisinin, the main component of first-line treatments for malaria. Clinical...
9.
Fukuda N, Tachibana S, Ikeda M, Sakurai-Yatsushiro M, Balikagala B, Katuro O, et al.
Parasitol Int
. 2020 Dec;
81:102277.
PMID: 33370608
In Uganda, artemether-lumefantrine was introduced as an artemisinin-based combination therapy (ACT) for malaria in 2006. We have previously reported a moderate decrease in ex vivo efficacy of lumefantrine in Northern...
10.
Kanoi B, Nagaoka H, White M, Morita M, Palacpac N, Ntege E, et al.
Front Immunol
. 2020 Jun;
11:893.
PMID: 32477363
Clinical immunity to malaria develops after repeated exposure to parasites. Broadly reactive antibodies against parasite antigens expressed on the surface of infected erythrocytes (variable surface antigens; VSAs) are candidates for...